Advances in the pharmacological management of heart failure with reduced ejection fraction: A narrative review

Read full text Summarise with VIRAT
Authors: Yash U. More, A. Patil Amarjeet, Ashok B. Giri
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Heart failure with reduced ejection fraction (HFrEF) is a chronic and progressive cardiovascular syndrome associated with high morbidity, mortality, and healthcare utilisation worldwide. Despite significant advances in cardiovascular medicine, patients with HFrEF continue to experience frequent hospitalisations and impaired quality of life. Over the past decade, an improved understanding of the complex pathophysiology of HFrEF, including neurohormonal activation, maladaptive ventricular remodelling, inflammation, and metabolic dysfunction, has driven the development of multiple disease-modifying pharmacotherapies and updated treatment paradigms. Methods: This narrative review synthesises contemporary evidence published between 2020 and 2025 on the pathophysiology and pharmacological management of HFrEF. Major randomised controlled trials, meta-analyses, and international guideline documents were reviewed to evaluate established and emerging therapies, including angiotensin receptor–neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, sodium–glucose cotransporter-2 inhibitors, and newer agents such as ivabradine, vericiguat, and omecamtiv mecarbil. Particular emphasis was placed on mechanisms of action, clinical outcomes, and the expanding role of clinical pharmacists and Pharm D professionals in optimising guideline-directed medical therapy. Conclusion: The management of HFrEF has evolved toward early, multidrug, guideline-directed therapy targeting multiple pathophysiological pathways. Integrating emerging pharmacological agents with pharmacist-led care models offers substantial potential to improve adherence, reduce hospital readmissions, and enhance long-term clinical outcomes in patients with HFrEF.

Fields of Study & Subjects

Heart Failure Treatment and Management Heart rate and cardiovascular health Cardiovascular Function and Risk Factors

Publication details

Journal / source
GSC Biological and Pharmaceutical Sciences
Volume
34
Issue
3
Pages
199–208
Publication date
28 March 2026
Language
EN